Evolent Health (EVH) Misses Q1 EPS by 6c, Offers Guidance

Evolent Health (NYSE: EVH) reported Q1 EPS of ($0.06), $0.06 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $297 million versus the consensus estimate of $286.77 million.

GUIDANCE:

Evolent Health sees Q2 2022 revenue of $290-305 million, versus the consensus of $285 million.

Evolent Health sees FY2022 revenue of $1.16-1.21 billion, versus the consensus of $1.16 billion.

For earnings history and earnings-related data on Evolent Health (EVH) click here.

You May Also Be Interested In

• Schlumberger (SLB) earnings in-line, revenue beats expectations
• American Express (AXP) down despite beating Q1 estimates on top and bottom lines
• Benchmark on Take-Two's (TTWO) GTV 6 Release: 'we anticipate that the game will not be released within the fiscal year and expect it to launch in fiscal 2026 instead'